RT Journal Article
T1 A plasma metabolomic signature discloses human breast cancer.
A1 Jové, Mariona
A1 Collado, Ricardo
A1 Quiles, José Luís
A1 Ramírez-Tortosa, Mari-Carmen
A1 Sol, Joaquim
A1 Ruiz-Sanjuan, Maria
A1 Fernandez, Mónica
A1 de la Torre Cabrera, Capilla
A1 Ramírez-Tortosa, Cesar
A1 Granados-Principal, Sergio
A1 Sánchez-Rovira, Pedro
A1 Pamplona, Reinald
K1 biomarker
K1 breast cancer
K1 mass spectrometry
K1 metabolites
K1 metabolomics
AB Metabolomics is the comprehensive global study of metabolites in biological samples. In this retrospective pilot study we explored whether serum metabolomic profile can discriminate the presence of human breast cancer irrespective of the cancer subtype. Plasma samples were analyzed from healthy women (n = 20) and patients with breast cancer after diagnosis (n = 91) using a liquid chromatography-mass spectrometry platform. Multivariate statistics and a Random Forest (RF) classifier were used to create a metabolomics panel for the diagnosis of human breast cancer. Metabolomics correctly distinguished between breast cancer patients and healthy control subjects. In the RF supervised class prediction analysis comparing breast cancer and healthy control groups, RF accurately classified 100% both samples of the breast cancer patients and healthy controls. So, the class error for both group in and the out-of-bag error were 0. We also found 1269 metabolites with different concentration in plasma from healthy controls and cancer patients; and basing on exact mass, retention time and isotopic distribution we identified 35 metabolites. These metabolites mostly support cell growth by providing energy and building stones for the synthesis of essential biomolecules, and function as signal transduction molecules. The collective results of RF, significance testing, and false discovery rate analysis identified several metabolites that were strongly associated with breast cancer. In breast cancer a metabolomics signature of cancer exists and can be detected in patient plasma irrespectively of the breast cancer type.
YR 2017
FD 2017
LK https://hdl.handle.net/10668/25127
UL https://hdl.handle.net/10668/25127
LA en
DS RISalud
RD Apr 12, 2025